A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma
Study of Drug E7777 in Cutaneous T-Cell Lymphoma - Cancer of T-lymphocytes (type of white blood cells) that Involves the Skin
Sponsor: Eisai
Enrolling: Male and Female Patients
IRB Number: AAAR7696
U.S. Govt. ID: NCT01871727
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of the Main study is to test the overall effects of E7777 on you and your illness. It is not known what effect E7777 will have on your illness or what the side effects will be. This study will look at the effect E7777 has on your body and your disease. It will also look at how your body absorbs, distributes, breaks down, and gets rid of the study drug. For patients who have a diagnosis of Cutaneous T-Cell Lymphoma (mycosis fungoides MF or Sezary Syndrome SS.
This study is closed
Investigator
Larisa Geskin, MD
Do You Qualify?
Are you 18 years or older? Yes No
Do you have a diagnosis of Cutaneous T-Cell Lymphoma (mycosis fungoides MF or Sezary Syndrome SS)? Yes No
Do you have a life expectancy of greater than or equal to 12 months? Yes No
Were you previously treated for Cutaneous T-Cell Lymphoma? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE